Mani Mohindru bought $30k of CRDF
Chief Executive Officer at Cardiff Oncology, Inc.. 24,703 shares at an average of $1.21, traded Jun 18, 2026, filed Jun 22, 2026.
Score components
- +25RoleCEO
- +5Trade size$30k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +18Price context3% above the 52-week low; 73% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001664708-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | POpen-market purchase Common Stock | +24,703 | $1.21 | $30k | 24,703 | Jun 22, 2026 |
Related signals
Other insiders at Cardiff Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 63Notable | Cardiff Oncology, Inc. | Mani Mohindru Chief Executive Officer | $50k 34,364 shares | +139% | |
| 71Notable | Cardiff Oncology, Inc. | Gary W Pace director | $1000k 687,285 shares | +51% | |
| 47Moderate | Cardiff Oncology, Inc. | Gary W Pace director | $37k 30,000 shares | +2% | |
| 60Notable | CRDFbuy Cardiff Oncology, Inc. | Gary W Pace director | $711k 290,000 shares | +27% | |
| 46Moderate | Cardiff Oncology, Inc. | James E. Levine Chief Financial Officer | $37k 7,716 shares | +13% | |
| 46Moderate | Cardiff Oncology, Inc. | Renee P Tannenbaum director | $34k 10,000 shares | +100% | |
| 64Notable | Cardiff Oncology, Inc. | Gary W Pace director | $940k 361,615 shares | +52% | |
| 34Weak | CRDFbuy Cardiff Oncology, Inc. | Gary W Pace director | $41k 30,000 shares | +4% | |
| 33Weak | CRDFbuy Cardiff Oncology, Inc. | Gary W Pace director | $22k 22,950 shares | +4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.